Arcutis Biotherapeutics (ARQT) Projected to Post Quarterly Earnings on Wednesday

Arcutis Biotherapeutics (NASDAQ:ARQT) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Arcutis Biotherapeutics to announce earnings of $0.0551 per share and revenue of $118.8520 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. The business had revenue of $105.40 million during the quarter, compared to the consensus estimate of $103.67 million. On average, analysts expect Arcutis Biotherapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Arcutis Biotherapeutics Trading Down 3.4%

ARQT stock opened at $25.94 on Tuesday. Arcutis Biotherapeutics has a 52 week low of $13.69 and a 52 week high of $31.77. The company has a market capitalization of $3.24 billion, a PE ratio of -864.38 and a beta of 1.49. The company’s 50-day simple moving average is $25.65 and its 200 day simple moving average is $24.68. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.46 and a current ratio of 2.68.

Insider Transactions at Arcutis Biotherapeutics

In related news, Director Howard G. Welgus sold 4,096 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.41, for a total transaction of $99,983.36. Following the sale, the director directly owned 38,378 shares of the company’s stock, valued at approximately $936,806.98. The trade was a 9.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sue-Jean Lin sold 4,946 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.38, for a total transaction of $120,583.48. Following the transaction, the director owned 27,567 shares of the company’s stock, valued at approximately $672,083.46. This represents a 15.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 10,334 shares of company stock worth $250,697. Company insiders own 9.40% of the company’s stock.

Institutional Trading of Arcutis Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its holdings in shares of Arcutis Biotherapeutics by 59.3% during the fourth quarter. Invesco Ltd. now owns 307,382 shares of the company’s stock worth $8,926,000 after buying an additional 114,430 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Arcutis Biotherapeutics during the 4th quarter valued at $255,000. Mackenzie Financial Corp acquired a new stake in shares of Arcutis Biotherapeutics during the 4th quarter valued at $1,374,000. NewEdge Advisors LLC grew its position in Arcutis Biotherapeutics by 209.0% during the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock worth $45,000 after acquiring an additional 1,045 shares during the last quarter. Finally, XTX Topco Ltd grew its position in Arcutis Biotherapeutics by 557.9% during the 4th quarter. XTX Topco Ltd now owns 74,358 shares of the company’s stock worth $2,159,000 after acquiring an additional 63,055 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of Arcutis Biotherapeutics in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Wednesday, June 24th. Finally, Wall Street Zen upgraded Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.00.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.